Evaluation of Core and Symbolic Capabilities During Due-Diligence Processes in New Biotechnology Firms

International Journal of Innovation and Technology Management: 11(6).

20 Pages Posted: 11 Feb 2015

Date Written: July 15, 2014

Abstract

This study discusses the role of core and symbolic capabilities during due-diligence processes when investing in companies in turbulent fields such as the biotechnology industry. The results indicate that investors' evaluations are hierarchal and are based on two premises. First, investors look for core capabilities - the characteristics that signal the potential for future success. They then search for symbolic elements, such as reputation, to confirm their decisions. The study expands earlier models of investors' evaluation processes. It also offers new insights for entrepreneurs of biotechnology firms.

Keywords: Investments; core capabilities; symbolic capabilities, biotechnology companies; evaluation; venture capital; entrepreneurs; investors; due-diligence process.

Suggested Citation

Klein, Galit, Evaluation of Core and Symbolic Capabilities During Due-Diligence Processes in New Biotechnology Firms (July 15, 2014). International Journal of Innovation and Technology Management: 11(6)., Available at SSRN: https://ssrn.com/abstract=2562350

Galit Klein (Contact Author)

Ariel University ( email )

Israel

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
44
Abstract Views
342
PlumX Metrics